White & Case advises EQT and Karo Intressenter on public cash offer for Karo Pharma
1 min read
Global law firm White & Case LLP has advised leading global investment firm EQT, through EQT VIII and Karo Intressenter AB (Karo Intressenter), on a public cash offer to the shareholders of Karo Pharma AB (Karo Pharma) to acquire the shares in Karo Pharma not already owned by Karo Intressenter.
The shareholders in Karo Pharma, which is listed on Nasdaq First North Growth Market and majority owned by EQT, are being offered SEK 60 in cash per share. The offer values the total number of shares in Karo Pharma to approximately SEK 16.4 billion (approximately US$1.6 billion).
EQT is a global investment organization with €77 billion in assets under management across 36 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately €29 billion and more than 280,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.
Headquartered in Sweden, Karo Pharma specializes in the sale and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and other retail outlets. Karo Pharma's products are available in more than 90 countries with the core offering in Europe and the Nordic region.
The White & Case team in Stockholm which advised on the transaction was led by partners Patrik Erblad and Johan Thiman, and included associates Izabella Barisa, Anna-Klara Hallingström, Fredrik Johansson and Zacharias Ngiam.
For more information please speak to your local media contact.